Related Experiment Video
Updated: Jul 4, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Silk polymer-based adenosine release: therapeutic potential for epilepsy.
Andrew Wilz1, Eleanor M Pritchard, Tianfu Li
1Robert Stone Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Avenue, Portland, OR 97232, USA.
Biomaterials
|June 3, 2008
Summary
Novel silk implants deliver adenosine to control seizures, offering a promising therapy for refractory epilepsy. This adenosine augmentation therapy (AAT) demonstrated a dose-dependent reduction in seizure activity in rat models.
Area of Science:
- Neuroscience
- Biomaterials Science
- Pharmacology
Background:
- Refractory epilepsy poses a significant therapeutic challenge.
- Adenosine augmentation therapies (AAT) leverage the brain's endogenous seizure control mechanisms.
- Developing safe and effective AAT delivery systems is crucial for clinical application.
Purpose of the Study:
- To develop a novel silk protein-based implant for sustained adenosine release.
- To evaluate the efficacy of adenosine-releasing implants in a rat model of epilepsy.
- To determine the optimal therapeutic dose for seizure suppression.
Main Methods:
- Silk fibroin scaffolds were engineered to encapsulate adenosine microspheres.
- In vitro release kinetics were assessed over 14 days.
- Adenosine implants were tested in a rat kindling model, monitoring seizure acquisition post-implantation.
Main Results:
- Silk implants demonstrated controlled adenosine release in vitro, matching target doses.
- Adenosine implants significantly retarded seizure acquisition in a dose-dependent manner.
- High-dose implants (819ng/day) delayed epileptogenesis by one week (18 stimulations).
Conclusions:
- Silk-based adenosine implants represent a safe and effective strategy for seizure suppression.
- This novel AAT delivery system shows potential for treating refractory epilepsy.
- Further research into clinical translation of these silk-based implants is warranted.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...